Start-up of the Week: MagiCup aims to become a global online store

Updated 19 September 2018
0

Start-up of the Week: MagiCup aims to become a global online store

People usually start their days with a cup of coffee or tea — and they would certainly enjoy their hot beverage more from a creatively designed cup.
MagiCup is a mug-designing Instagram store. It offers cups with various designs, colors and sizes, magic cups that change color with heat, and travel mugs.
It was established in May 2018. Customers can customize their own cups with their desired designs.
The co-owner of the store, Futoon Saif, explained the inspiration behind creating the store from her background in interior design.
“When I was a student in the interior design field, I realized how good designs have an affect on our lives; they affect everything around us, even the small products we use daily like mugs.
“Me and my partner Majed started MagiCup because we know how lovely it is for people to start their morning with their favorite cup that is designed.”
She said that mugs will always sell no matter what. “We choose to design cups because these are the things that are never going to be replaced by technology, and people for sure won’t stop using cups, so we want to keep on making wonderful designs for people to start their days with.”
Designing mugs is quite a process.
“In the beginning, we start by deciding which kind of mug we are going to use, the normal sized or small sized one, or the travel mug. After that, we start making the design that is going to be printed on the mug, and when we finish the design we create a mock-up for it to make sure it’s going to look good. The last step is that we print the design on a custom paper and print it on the mug itself.”
MagiCup wants to expand its reach and become a global online store.
“We will not open a physical store, but our store is going to be an online store that will serve you much better than a physical one. It is also an advantage that we make our store come to you rather than you come to it.”
She explained the connection the designs on the cups have with their owners. “I learned that designing is storytelling and I just want to make our clients day happy by designing their stories on their lovely cups.”
Saif said that MagiCup strives to achieve customer satisfaction.
“We take our customer’s idea and add our own twist to it. Even if it was a ready-made picture or design, we adjust it, consult and follow up with the customer,” she said.


Jazz Pharma’s sleep disorder treatment gets US FDA nod

Updated 21 March 2019
0

Jazz Pharma’s sleep disorder treatment gets US FDA nod

  • The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea
  • The patent of Jazz's narcolepsy drug, Xyrem, were declared invalid by a US appeals court in July
The US Food and Drug Administration approved Jazz Pharmaceuticals Plc’s treatment for patients with a form of sleep disorder, the company said on Wednesday.
The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
Solriamfetol is expected to be commercially available in the United States following the final scheduling decision by the Drug Enforcement Administration (DEA), Jazz said in a statement.
The approval comes as Jazz is trying to reduce its reliance on its blockbuster narcolepsy drug, Xyrem, whose patents were declared invalid by a US appeals court in July.
Xyrem is an approved treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy. It brought in sales of $1.4 billion in 2018 and accounted for about 70 percent of company’s revenue.
“Jazz is trying to reduce its reliance on Xyrem, and solriamfetol will be one of the drugs it plans to launch to do that,” Mizuho Securities USA analyst Irina Koffler said ahead of the agency’s decision.
“Solriamfetol is expected to be an important driver of both diversification and growth,” RBC Capital Markets analyst Randall Stanicky said in a note ahead of the approval.
Solriamfetol is expected to bring in revenue of $314 million by 2024, Stanicky said.
Narcolepsy is a chronic sleep disorder with overwhelming daytime drowsiness and sudden attacks of sleep, while obstructive sleep apnea is a potentially serious sleep disorder that can cause breathing to repeatedly stop and start.
“Narcolepsy is very disabling to people as they often get diagnosed young and stop their education and drop out of high school or college,” Koffler said.
“Sleep apnea is a different problem in the sense that a lot of people don’t know they have it, have trouble breathing at night and they even fall asleep during the day.”